Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group
Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria)....
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
[April 10 2010]
|
| In: |
Journal of clinical oncology
Year: 2010, Jahrgang: 28, Heft: 11, Pages: 1963-1972 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.2009.26.3541 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.2009.26.3541 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.2009.26.3541 
|
| Verfasserangaben: | Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen, Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien, Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn, Michael A. Vogelbaum, Martin J. van den Bent, and Susan M. Chang |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1869153774 | ||
| 003 | DE-627 | ||
| 005 | 20240311121829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231103s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.2009.26.3541 |2 doi | |
| 035 | |a (DE-627)1869153774 | ||
| 035 | |a (DE-599)KXP1869153774 | ||
| 035 | |a (OCoLC)1425873061 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wen, Patrick Y. |e VerfasserIn |0 (DE-588)1205842608 |0 (DE-627)1691570818 |4 aut | |
| 245 | 1 | 0 | |a Updated response assessment criteria for high-grade gliomas |b response assessment in Neuro-Oncology Working Group |c Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen, Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien, Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn, Michael A. Vogelbaum, Martin J. van den Bent, and Susan M. Chang |
| 264 | 1 | |c [April 10 2010] | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.11.2023 | ||
| 520 | |a Currently, the most widely used criteria for assessing response to therapy in high-grade gliomas are based on two-dimensional tumor measurements on computed tomography (CT) or magnetic resonance imaging (MRI), in conjunction with clinical assessment and corticosteroid dose (the Macdonald Criteria). It is increasingly apparent that there are significant limitations to these criteria, which only address the contrast-enhancing component of the tumor. For example, chemoradiotherapy for newly diagnosed glioblastomas results in transient increase in tumor enhancement (pseudoprogression) in 20% to 30% of patients, which is difficult to differentiate from true tumor progression. Antiangiogenic agents produce high radiographic response rates, as defined by a rapid decrease in contrast enhancement on CT/MRI that occurs within days of initiation of treatment and that is partly a result of reduced vascular permeability to contrast agents rather than a true antitumor effect. In addition, a subset of patients treated with antiangiogenic agents develop tumor recurrence characterized by an increase in the nonenhancing component depicted on T2-weighted/fluid-attenuated inversion recovery sequences. The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies. The Response Assessment in Neuro-Oncology Working Group is an international effort to develop new standardized response criteria for clinical trials in brain tumors. In this proposal, we present the recommendations for updated response criteria for high-grade gliomas. | ||
| 700 | 1 | |a Macdonald, David R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reardon, David A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cloughesy, Timothy F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sorensen, A. Gregory |e VerfasserIn |4 aut | |
| 700 | 1 | |a Galanis, Evanthia |e VerfasserIn |4 aut | |
| 700 | 1 | |a DeGroot, John |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 700 | 1 | |a Gilbert, Mark R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lassman, Andrew B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tsien, Christina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mikkelsen, Tom |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wong, Eric T. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chamberlain, Marc C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stupp, Roger |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lamborn, Kathleen R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vogelbaum, Michael A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bent, Martin J. van den |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chang, Susan M. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 28(2010), 11, Seite 1963-1972 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Updated response assessment criteria for high-grade gliomas response assessment in Neuro-Oncology Working Group |
| 773 | 1 | 8 | |g volume:28 |g year:2010 |g number:11 |g pages:1963-1972 |g extent:10 |a Updated response assessment criteria for high-grade gliomas response assessment in Neuro-Oncology Working Group |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.2009.26.3541 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.2009.26.3541 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231103 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 8 | ||
| 999 | |a KXP-PPN1869153774 |e 440139609X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"origin":[{"publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedKey":"1983","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}],"disp":"Updated response assessment criteria for high-grade gliomas response assessment in Neuro-Oncology Working GroupJournal of clinical oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"313116962","part":{"year":"2010","volume":"28","pages":"1963-1972","extent":"10","text":"28(2010), 11, Seite 1963-1972","issue":"11"},"id":{"eki":["313116962"],"issn":["1527-7755"],"zdb":["2005181-5"]},"corporate":[{"display":"American Society of Clinical Oncology","role":"isb"}],"pubHistory":["1.1983 -"],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}]}],"person":[{"family":"Wen","given":"Patrick Y.","role":"aut","display":"Wen, Patrick Y."},{"display":"Macdonald, David R.","family":"Macdonald","given":"David R.","role":"aut"},{"family":"Reardon","given":"David A.","role":"aut","display":"Reardon, David A."},{"display":"Cloughesy, Timothy F.","role":"aut","given":"Timothy F.","family":"Cloughesy"},{"display":"Sorensen, A. Gregory","family":"Sorensen","role":"aut","given":"A. Gregory"},{"display":"Galanis, Evanthia","family":"Galanis","role":"aut","given":"Evanthia"},{"display":"DeGroot, John","family":"DeGroot","given":"John","role":"aut"},{"family":"Wick","role":"aut","given":"Wolfgang","display":"Wick, Wolfgang"},{"family":"Gilbert","role":"aut","given":"Mark R.","display":"Gilbert, Mark R."},{"display":"Lassman, Andrew B.","family":"Lassman","role":"aut","given":"Andrew B."},{"display":"Tsien, Christina","family":"Tsien","role":"aut","given":"Christina"},{"role":"aut","given":"Tom","family":"Mikkelsen","display":"Mikkelsen, Tom"},{"display":"Wong, Eric T.","family":"Wong","given":"Eric T.","role":"aut"},{"display":"Chamberlain, Marc C.","given":"Marc C.","role":"aut","family":"Chamberlain"},{"family":"Stupp","given":"Roger","role":"aut","display":"Stupp, Roger"},{"display":"Lamborn, Kathleen R.","role":"aut","given":"Kathleen R.","family":"Lamborn"},{"display":"Vogelbaum, Michael A.","family":"Vogelbaum","role":"aut","given":"Michael A."},{"family":"Bent","given":"Martin J. van den","role":"aut","display":"Bent, Martin J. van den"},{"family":"Chang","role":"aut","given":"Susan M.","display":"Chang, Susan M."}],"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"[April 10 2010]"}],"note":["Gesehen am 03.11.2023"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Updated response assessment criteria for high-grade gliomas","title_sort":"Updated response assessment criteria for high-grade gliomas","subtitle":"response assessment in Neuro-Oncology Working Group"}],"physDesc":[{"extent":"10 S."}],"recId":"1869153774","name":{"displayForm":["Patrick Y. Wen, David R. Macdonald, David A. Reardon, Timothy F. Cloughesy, A. Gregory Sorensen, Evanthia Galanis, John DeGroot, Wolfgang Wick, Mark R. Gilbert, Andrew B. Lassman, Christina Tsien, Tom Mikkelsen, Eric T. Wong, Marc C. Chamberlain, Roger Stupp, Kathleen R. Lamborn, Michael A. Vogelbaum, Martin J. van den Bent, and Susan M. Chang"]},"id":{"doi":["10.1200/JCO.2009.26.3541"],"eki":["1869153774"]}} | ||
| SRT | |a WENPATRICKUPDATEDRES1020 | ||